Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection
Status:
Terminated
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
Apricitabine is a new NRTI which is active against drug-resistant HIV. NRTIs are often
included as part of patients' treatment, but many HIV-infected patients develop resistance to
commonly used NRTIs such as lamivudine (3TC) and emtricitabine (FTC). This study will examine
whether including apricitabine as part of patients' treatment is more effective than
including lamivudine,when patients change treatment because of drug resistance.